SEC 13F Intelligence

Managers / Q2 2024 · view latest →

Exome Asset Management LLC

CIK 0002011932 · 330 MADISON AVENUE, NEW YORK, NY, 10017 · 212-403-3900

Reported Value
$115M
Q2 2024
Positions
50
Filings on Record
14
2019–present window
Filed
Aug 14, 2024
original filing

Summary

Exome Asset Management LLC reported $115M in U.S.-listed holdings across 50 positions for Q2 2024.

Its largest position, LLY, represents 7.6% of the portfolio.

Compared with Q1 2024, the fund opened 27 new positions and exited 30.

Portfolio Metrics

Turnover
+59.1%
vs prior filed quarter
Top-10 Concentration
+42.4%
share of reported value
Largest Position
+7.6%
Eli Lilly
New / Exited
27 / 30
positions this quarter

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q4 ’23: $101MQ4 ’23Q1 ’24: $117MQ2 ’24: $115MQ2 ’24Q3 ’24: $146MQ4 ’24: $133MQ4 ’24Q1 ’25: $112MQ2 ’25: $135MQ2 ’25Q3 ’25: $165MQ4 ’25: $209MQ4 ’25Q1 ’26: $193Mfilingsflow.com

Portfolio Composition

By security type
Common Stock: 69.6%Other: 21.2%ADR: 9.2%
  • Common Stock · 69.6% · $80M
  • Other · 21.2% · $24M
  • ADR · 9.2% · $11M

Quarter-over-Quarter Changes full breakdown →

vs Q1 2024 (amended baseline)

IssuerMoveShare ΔShares nowValue ΔValue now
MERUS N VNEW+74.0K74.0K+$7M$7M
SRPTSAREPTA THERAPEUTICS INCNEW+32.9K32.9K+$5M$5M
WAVE LIFE SCIENCES LTDNEW+496.6K496.6K+$4M$4M
AMGNAMGEN INCNEW+11.8K11.8K+$4M$4M
AVADEL PHARMACEUTICALS PLCNEW+209.1K209.1K+$3M$3M
AUTLAUTOLUS THERAPEUTICS PLCNEW+839.5K839.5K+$3M$3M
IRONDISC MEDICINE INCNEW+61.0K61.0K+$3M$3M
ASCENDIS PHARMA A/SNEW+20.0K20.0K+$3M$3M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q2 2024

50 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1LLYELI LILLY & COhistory →COM7.65%$9M9.7K
2MERUS N VCOM5.91%$7M74.0K
3SRPTSAREPTA THERAPEUTICS INChistory →COM4.53%$5M32.9K
4TGTXTG THERAPEUTICS INChistory →COM3.90%$4M251.6K
5WAVE LIFE SCIENCES LTDSHS3.84%$4M496.6K
6CITHE CIGNA GROUPhistory →COM3.51%$4M12.2K
7CRBPCORBUS PHARMACEUTICALS HLDGShistory →COM NEW3.34%$4M84.8K
8IM8NINSMED INChistory →COM PAR $.013.31%$4M56.8K
9AMGNAMGEN INChistory →COM3.21%$4M11.8K
10TVTXTRAVERE THERAPEUTICS INChistory →COM3.17%$4M443.4K
11MDGLMADRIGAL PHARMACEUTICALS INChistory →COM2.63%$3M10.8K
12AVADEL PHARMACEUTICALS PLCCOM SHS2.56%$3M209.1K
13DC4DEXCOM INChistory →COM2.56%$3M25.9K
14AUTLAUTOLUS THERAPEUTICS PLChistory →SPON ADS2.54%$3M839.5K
15ISRGINTUITIVE SURGICAL INChistory →COM NEW2.46%$3M6.4K
16DR REDDYS LABS LTDADR2.41%$3M36.3K
17IRONDISC MEDICINE INChistory →COM2.39%$3M61.0K
18ASCENDIS PHARMA A/SSPONSORED ADR2.37%$3M20.0K
19KURAKURA ONCOLOGY INChistory →COM2.36%$3M131.7K
20BIOHAVEN LTDCOM2.21%$3M90.2K
21MASI*MASIMO CORPhistory →COM2.17%$2M19.8K
22260CENTESSA PHARMACEUTICALS PLChistory →SPONSORED ADS2.16%$2M274.9K
23GHGUARDANT HEALTH INChistory →COM1.99%$2M79.0K
24CABACABALETTA BIO INChistory →COM1.96%$2M300.2K
25ARVNARVINAS INChistory →COM1.91%$2M82.4K
26NTRANATERA INChistory →COM1.76%$2M18.6K
27BBIOBRIDGEBIO PHARMA INChistory →COM1.74%$2M78.9K
28FULCFULCRUM THERAPEUTICS INChistory →COM1.63%$2M302.7K
29APLSUSDAPELLIS PHARMACEUTICALS INChistory →COM1.57%$2M46.9K
30ATECALPHATEC HLDGS INChistory →COM NEW1.47%$2M162.1K
31ESTABLISHMENT LABS HLDGS INCCOM1.39%$2M26.0K
32ABCLABCELLERA BIOLOGICS INChistory →COM1.33%$2M514.9K
33ZLABZAI LAB LTDhistory →ADR1.31%$2M86.7K
34PLRXPLIANT THERAPEUTICS INChistory →COM1.16%$1M124.0K
35RZLTREZOLUTE INChistory →COM NEW1.06%$1M282.4K
36ALVOTECHORDINARY SHARES1.05%$1M99.0K
37GOSSGOSSAMER BIO INCCOM0.88%$1M1.13M
38ELEVATION ONCOLOGY INCCOM0.87%$997,170369.3K
39PROCAPS GROUP SASHS0.76%$877,428129.3K
40SYROS PHARMACEUTICALS INCCOM NEW0.72%$821,344159.2K
41QTRXQUANTERIX CORPCOM0.69%$787,97659.6K
42QTTBQ32 BIO INCCOM0.69%$787,37643.9K
43VYNEVYNE THERAPEUTICS INCCOM0.61%$696,264353.4K
44PMVPPMV PHARMACEUTICALS INCCOM0.51%$580,608358.4K
45APREAPREA THERAPEUTICS INCCOM NEW0.49%$558,298137.2K
46ADAGADAGENE INCADS0.40%$461,832150.9K
47NBPI MABSPONSORED ADS0.39%$453,238271.4K
48HILLEVAX INCCOM0.23%$260,28018.0K
49SGMTSAGIMET BIOSCIENCES INCCOM SER A0.15%$173,39450.7K
50PACBPACIFIC BIOSCIENCES CALIF INCOM0.09%$103,16275.3K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q1 2026$193M56May 15, 202613F-HRchanges · EDGAR ↗
Q4 2025$209M60Feb 13, 202613F-HRchanges · EDGAR ↗
Q3 2025$165M68Nov 14, 202513F-HRchanges · EDGAR ↗
Q2 2025$135M63Aug 15, 2025RESTATEMENTchanges · EDGAR ↗
Q1 2025$112M59May 16, 2025RESTATEMENTchanges · EDGAR ↗
Q4 2024$133M59Feb 14, 202513F-HRchanges · EDGAR ↗
Q3 2024$146M56Nov 14, 202413F-HRchanges · EDGAR ↗
Q2 2024$115M50Aug 14, 202413F-HRchanges · EDGAR ↗
Q1 2024$117M53May 15, 202413F-HRchanges · EDGAR ↗
Q4 2023$101M52Feb 15, 202413F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.